Management of malignant Melanoma: Best practices

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue 2, 2009, Pages 55-73

  Smylie, Michael ^{a,b,c,d,e,f,g}   Claveau, Jöel ^{a,b,c,d,e,f,g}   Alanen, Kenneth ^{a,b,c,d,e,f,g}   Taillefer, Raymond ^{a,b,c,d,e,f,g}   George, Ralph ^{a,b,c,d,e,f,g}   Wong, Ralph ^{a,b,c,d,e,f,g}   Mason, Warren P ^{a,b,c,d,e,f,g}  

^a CROSS CANCER INSTITUTE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Kingston Regional Cancer Center   (Canada)

^f ST BONIFACE GENERAL HOSPITAL   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIMONY TECHNETIUM SULFIDE TC 99M; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DACARBAZINE; DEXAMETHASONE; INTERLEUKIN 2; NARCOTIC ANALGESIC AGENT; PARACETAMOL; SEROTONIN; TECHNETIUM SULFUR COLLOID TC 99M; TEMOZOLOMIDE; THALIDOMIDE; TRACER; ALKYLATING AGENT; DRUG DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; ANALYTICAL PARAMETERS; ANOREXIA; ARTICLE; BRAIN METASTASIS; BRESLOW THICKNESS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CASE MANAGEMENT; CHILL; CHRONIC DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IN-TRANSIT METASTASIS; INFORMATION PROCESSING; INTRAOPERATIVE GAMMA PROBE; JUVENILE MELANOMA; LYMPHOSCINTIGRAPHY; MELANOMA; METASTASIS; MITOSIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPATHY; RADIODIAGNOSIS; RADIOLOGICAL PROCEDURES; RIGOR; SATELLITE METASTASIS; SEIZURE; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; SKIN BIOPSY; SKIN ULCER; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; BRAIN TUMOR; INTRAOPERATIVE PERIOD; PATHOLOGY; QUALITY CONTROL; REVIEW; SKIN TUMOR;

ANTINEOPLASTIC AGENTS, ALKYLATING; BENCHMARKING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; HUMANS; INTRAOPERATIVE PERIOD; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 67649771329     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.08029     Document Type: Article

References (65)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2005. Available at: http://www.ncic.cancer.ca (accessed October 13, 2005).
2. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003;97:639-43.
3. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41:2040-59.
4. Greene MH, Clark WH, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65.
5. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
6. Tannous ZS, Mihm MC, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005; 52:197-203.
7. Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. Int J Cancer 1995;62: 367-76.
8. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198-203.
9. Tsao H, Sober AJ. Ultraviolet radiation and malignant melanoma. Clin Dermatol 1998;16:67-73.
10. Sober A, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579-86.
11. NIH consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.
12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology, v.1.2006. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/melanoma.pdf (accessed January 30, 2006).
13. National Health and Medical Research Council and the Australian Cancer Network. Clinical practice guidelines: the management of cutaneous melanoma, December 1999. Available at: http://www7.health.gov.au/nhmrc/ publications/_files/cp68.pdf (accessed January 30, 2006).
14. Négrier S, Saiag P, Guillot B, et al. Recommandations pour la Pratique Clinique: Standards, Options et Recommandations 2005 pour la prise en charge des patients adultes atteints d'un mélanome cutane MO. Ann Dermatol Venereol 2005;132:10.
15. Roberts DL, Anstey AV, Barlow RJ, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146:7-17.
16. Rigel DS, Friedman RJ, Kopf AW, Polsky D. ABCDE - an evolving concept in the early detection of melanoma. Arch Dermatol 2005; 141:1032-4.
17. Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003;48:679-93.
18. Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34:2420-53.
19. Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005;52:92-100.
20. Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative staging manual and coding instructions, version 1.0. Chicago and Bethesda (MD): American Joint Committee on Cancer and US Department of Health and Human Services; 2004. NIH Publication No.: 04-5496.
21. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
22. Spatz A, Cook MG, Elder DE, et al. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer 2003;39:1861-5.
23. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
24. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-41.
25. Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996;20:834-40.
26. Kelley SW, Cockerell CJ. Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: a proposal. J Am Acad Dermatol 2000;42:527-30.
27. Lohmann CM, Coit DG, Brady MS, et al. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 2002;26:47-55.
28. LeBoit PE. What do these cells prove? Am J Dermatopathol 2003; 25:355-6.
29. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-70.
30. Biddle DA, Evans HL, Kemp BL, et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol 2003;27: 673-81.
31. Cochran AJ. Studies of the melanocytes of the epidermis adjacent to tumors. J Invest Dermatol 1971;57:38-43.
32. Handley WS. The pathology of melanotic growth in relation to their operative treatment. Lancet 1907;1:927.
33. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann Surg 1993;218:262-7.
34. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins 1 or 3 cm. N Engl J Med 1988;318:1159-62.
35. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and metaanalysis. Can J Surg 2003;46:419-26.
36. Coit D, Wallack M, Balch C. Society of Surgical Oncology practice guidelines. Melanoma surgical practice guidelines. Oncology (Williston Park) 1997;11:1317-23.
37. Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin Dissection in malignant melanoma. Ann Surg Oncol 1994;1:271-7.
38. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-91.
39. Chao C, Wong SL, Edwards MJ, et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol 2003;10:21-6.
40. Schmalbach CE, Nussenbaum B, Rees RS, et al. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg 2003;129: 61-5.
41. Karakousis CP, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma. Ann Surg Oncol 1999;6:785-9.
42. Karakousis CP, Bland KI, Balch CM. Neoplasms of the skin. In: Bland KI, Daly JM, Constantine P, editors. Surgical oncology: contemporary principle and practice. New York: McGraw-Hill; 2001. p. 483-519.
43. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003;10:676-80.
44. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002;9:762-70.
45. Tsao H, Atkins MB, Sober A. J. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
46. Atkins MB, Lotze MT, Dutcher JP, et al. High dose interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17: 2105-16.
47. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
48. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991;18 (5 Suppl 7):83-9.
49. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989;16 (1 Suppl 1):34p-44.
50. Saha S, Meyer M, Krementz ET, et al. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann Surg Oncol 1994;1:38-44.
51. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978;42:660-8.
52. Madajewicz S, Karakousis C, West CR, et al. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 1984;53:2550-2.
53. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978;42:660-8.
54. Sirven JL, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta analysis. Mayo Clin Proc 2004;79:1489-94.
55. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
56. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-90.
57. Carella RJ, Gelber R, Hendrickson F, et al. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group brain metastases study I and II. Cancer 1980;45:679-83.
58. Somaza S, Kondziolka D, Lunsford LD, et al. Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 1993;79:661-6.
59. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5: 144-51.
60. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166.
61. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001; 345:621-2.
62. Margolin K, Atkins MB, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214-8.
63. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003;21:3351-6.
64. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2001;2:634-5.
65. Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12:175-8.